论文部分内容阅读
目的:通过检测前列腺癌患者以及健康志愿者外周血中CD4+CD25high调节性T细胞、TGF-β1及COX-2的表达,初步探讨CD4+CD25high调节性T细胞在前列腺癌发病机制中的作用及其与TGF-β1和COX-2的相关性。方法:应用流式细胞术检测30例前列腺癌患者治疗前后(其中前列腺癌局限组11例,非局限组19例)及20例健康志愿者外周血单个核细胞(PBMC)中CD4+CD25high调节性T细胞占CD4+T细胞的比例;应用酶联免疫吸附试验(ELISA)检测其外周血清中TGF-β1和COX-2的表达。对前列腺癌患者上述指标进行术前术后对比分析,另对CD4+CD25high调节性T细胞与TGF-β1及COX-2的相关性进行分析;并探讨上述指标在前列腺癌患者局限组和非局限组间是否存在差异性。结果:流式细胞术检测显示,前列腺癌患者治疗前PBMC中CD4+CD25high调节性T细胞占CD4+T细胞的比例为(18.32±7.49)%,高于健康志愿者对照组(7.77±1.86)%(P<0.05)。前列腺癌患者治疗后其比值为(17.34±5.87)%,较治疗前稍减低,但两者相比无显著差异(P>0.05)。ELISA检测外周血清中TGF-β1和COX-2显示,前列腺癌组分别为(215.97±55.16)ng/ml和(6.88±5.14)ng/ml,对照组分别为(149.75±47.11)ng/ml和(5.65±2.69)ng/ml;前列腺癌患者外周血清中TGF-β1的表达水平高于健康志愿者对照组(P<0.05),COX-2的表达水平与对照组无显著差异(P>0.05)。通过多重线性回归分析表明,前列腺癌患者PBMC中CD4+CD25high调节性T细胞的表达与血清中TGF-β1和COX-2的表达无显著相关。前列腺癌局限组和非局限组外周血中CD4+CD25high调节性T细胞、TGF-β1及COX-2的表达均无显著性差异(P>0.05)。结论:前列腺癌患者PBMC中CD4+CD25high调节性T细胞可能参与前列腺癌的发生,其增殖机制与血清中TGF-β1和COX-2的表达无关,可能与肿瘤本身及肿瘤局部微环境相关。
Objective: To investigate the role of CD4 + CD25high regulatory T cells in the pathogenesis of prostate cancer by detecting the expression of CD4 + CD25high regulatory T cells, TGF-β1 and COX-2 in peripheral blood of patients with prostate cancer and healthy volunteers Its correlation with TGF-β1 and COX-2. Methods: Flow cytometry was used to detect CD4 + CD25high regulatory activity in peripheral blood mononuclear cells (PBMCs) of 30 patients with prostate cancer before and after treatment (including 11 patients with localized prostate cancer and 19 patients without restriction) and 20 healthy volunteers T cells in CD4 + T cells. The expression of TGF-β1 and COX-2 in peripheral blood was detected by enzyme-linked immunosorbent assay (ELISA). Preoperative and postoperative comparisons of the above parameters were performed in patients with prostate cancer. The correlation between CD4 + CD25high regulatory T cells and TGF-β1 and COX-2 was also analyzed. The above indexes were also compared with those in patients with localized prostate cancer Is there any difference between groups? Results: Flow cytometry showed that the proportion of CD4 + CD25high regulatory T cells to CD4 + T cells in PBMCs was (18.32 ± 7.49)% in prostate cancer patients before treatment, which was significantly higher than that in healthy volunteers (7.77 ± 1.86) % (P <0.05). The ratio of prostate cancer patients after treatment was (17.34 ± 5.87)%, slightly lower than that before treatment, but there was no significant difference between the two groups (P> 0.05). The levels of TGF-β1 and COX-2 in peripheral blood were detected by ELISA (215.97 ± 55.16) ng / ml and (6.88 ± 5.14) ng / ml respectively in the prostate cancer group and 149.75 ± 47.11 ng / ml in the control group (5.65 ± 2.69) ng / ml respectively. The expression of TGF-β1 in peripheral blood of patients with prostate cancer was higher than that of healthy volunteers (P <0.05), while the expression of COX-2 was not significantly different from that of the control group ). Multiple linear regression analysis showed that there was no significant correlation between the expression of CD4 + CD25high regulatory T cells and the levels of TGF-β1 and COX-2 in PBMC of patients with prostate cancer. There was no significant difference in the expression of CD4 + CD25high regulatory T cells, TGF-β1 and COX-2 in the peripheral blood of patients with localized prostate cancer and non-localized prostate cancer (P> 0.05). Conclusion: CD4 + CD25high regulatory T cells in PBMC from patients with prostate cancer may be involved in the pathogenesis of prostate cancer. The mechanism of proliferation is not related to the expression of TGF-β1 and COX-2 in serum, which may be related to tumor itself and tumor microenvironment.